EAN President Paul Boon and ESNR President Tarek Yousry are pleased to announce that a Memorandum of Understanding has been signed between the EAN and ESNR.

Make the most of your research by publishing in the official EAN journal, with double-digit annual growth in submissions and readership.

Read the latest three reports on EAN Student Teaser Fellowships that took place in 2022. Find out how our future neurologists got on in their chosen departments.

In July, the World Health Organization (WHO) published the Intersectoral global action plan on epilepsy and other neurological disorders (IGAP) in all six UN languages.

This year marks a great occasion in the history of our organization as we proudly celebrate the 20-year work anniversary of EAN's Executive Director, Anja Sander!

On 26 July, the World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc) which include important new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions, among others.

The Brain Health Mission was an unmissable feature of the exhibition at the EAN Congress 2023 in Budapest. With its bicycle-powered smoothie maker, reading lounge, and giveaways, the bright green stand attracted lots of comments - literally, written all over its walls!

Reports from three EAN Clinical Fellowship participants on their experiences in Heemstede (NL). Ljubljana, and Belgrade.

The programme for the 33rd Alzheimer Europe Conference (16-18 October) is now available on the Alzheimer Europe website.

A Special Session at the EAN Congress 2023 welcomed two guests from the African Academy of Neurology (AFAN), to discuss shortages, challenges, education and training across the African continent.

Re-live some of the highlights of the EAN Congress 2023 with our Congress Review, full of session reports, photos, facts and figures from Europe’s biggest neurology meeting.

EAN President Paul Boon looks back at the 9th Congress of the European Academy of Neurology, which took place in Budapest on 1-4- July.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2023.

The 3rd edition of the Brain Innovation Days, organised by the European Brain Council, will take place on 26-27 October 2023 in Brussels (Belgium) under the overarching theme 'The Brain in the 21st Century'.